Biogen Inc. $BIIB Shares Sold by Bokf Na

Key Points

• Bokf Na trimmed its stake by 26.7%, selling 5,412 shares and leaving 14,868 Biogen shares valued at about $2.62 million, per the latest SEC filing.
• Analysts' views are mixed: Wolfe Research and Needham project multi‑year upside while reaffirmations like Canaccord support the buy case, but both Wolfe and Needham sharply cut Q2 2026 EPS estimates, adding near‑term uncertainty.
• Recent results and guidance show momentum—Biogen beat quarterly EPS and revenue estimates, set FY2026 guidance of $14.25–$15.25 EPS, and the Street's average price target is roughly $214.23 (consensus: Moderate Buy).

Bokf Na trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 26.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,868 shares of the biotechnology company's stock after selling 5,412 shares during the period. Bokf Na's holdings in Biogen were worth $2,617,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BIIB. WPG Advisers LLC lifted its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC lifted its position in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 185 shares during the period. First Horizon Corp acquired a new stake in Biogen in the fourth quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in Biogen in the second quarter worth approximately $32,000. Finally, GoalVest Advisory LLC acquired a new stake in Biogen in the fourth quarter worth approximately $35,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wolfe Research and Needham published multi‑year upside: Wolfe projects FY2027–FY2030 EPS rising to $17.59, $18.94 and $21.17 (FY30), signaling stronger long‑term growth expectations; Needham’s longer‑range numbers (FY2027–FY2030) are also above current consensus in some years. These upward longer‑term views support a constructive medium/long‑term thesis.
• Positive Sentiment: Canaccord Genuity reaffirmed a Buy on BIIB, providing some buy‑side support for the shares. Canaccord Genuity Sticks to Its Buy Rating for Biogen (BIIB)
• Neutral Sentiment: Barclays and BMO Capital both maintained Hold ratings on BIIB — this keeps a portion of the broker community neutral rather than adding downward pressure. Barclays Keeps Their Hold Rating on Biogen (BIIB) BMO Capital Reaffirms Their Hold Rating on Biogen (BIIB)
• Neutral Sentiment: An unrelated press item on Giant Biogene (HK:2367) appeared in feeds; it does not pertain to Biogen (BIIB) but may have cluttered news flow. Giant Biogene Sets 2026 AGM
• Negative Sentiment: Wolfe Research cut its Q2 2026 EPS estimate sharply (from $3.78 to $3.11), a near‑term downgrade that could pressure sentiment around upcoming quarterly performance.
• Negative Sentiment: Needham also slashed its Q2 2026 EPS estimate (from $4.40 to $2.90), another notable near‑term revision that increases uncertainty for the next reported quarter.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $191.38 on Friday. Biogen Inc. has a one year low of $115.25 and a one year high of $202.41. The stock has a fifty day moving average of $184.27 and a 200-day moving average of $177.50. The company has a market capitalization of $28.25 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 1.67 and a beta of 0.19. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts' consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. The company's quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts anticipate that Biogen Inc. will post 14.31 EPS for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company's stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on BIIB. Citigroup increased their target price on shares of Biogen from $190.00 to $200.00 and gave the company a "neutral" rating in a research note on Friday, May 1st. Weiss Ratings upgraded Biogen from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, May 1st. JPMorgan Chase & Co. increased their price objective on Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a research report on Thursday, April 23rd. Barclays began coverage on Biogen in a research report on Thursday, February 19th. They set an "equal weight" rating and a $185.00 price objective for the company. Finally, Oppenheimer increased their price objective on Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research report on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $214.23.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.